[Pharmacotherapy of cardiac arrhythmias in women--what do we know, do we have a choice?].
The paper presents basic epidemiological, electrophysiological and therapeutical differences of cardiac arrhythmias depended on gender. Inadequate sinus tachycardia, orthostatic tachycardia syndrome and atrioventricular nodal reentrant tachycardia are more common in women as well as prolongation of QT interval and proarrhythmic phenomenon (especially torsade de pointes). Atrial fibrillation, although significantly less common in women, is more onerous, therapeutic aims are worse to achieve and outcomes are less favourable than in men. European guidelines do not recommend different pharmacological treatement of supraventricular and ventricular arrhythmias in relation to gender. Older antyarrhythmic drugs (beta-adrenolytics, amiodarone, sotalol) and as well as newer ones (dronedarone, ivabradine, vernakalant and ranolazine) seem to have the same influence on arrthythmias both in men and women, althouth their long-term safety may be different and depend on influence on QT interval. The paper presents the state of the art of antiarrhythmic drugs that might be prefered among woman in different clinical situations.